{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:20:46Z","timestamp":1793370046115,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmoop.2025.105128","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:51:19Z","timestamp":1748854279000},"page":"105128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care"],"prefix":"10.1016","volume":"10","author":[{"given":"C.","family":"Dauccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lobo-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Casalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105128_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamacardio.2016.3841","article-title":"A population-based study of cardiovascular mortality following early-stage breast cancer","volume":"2","author":"Abdel-Qadir","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.esmoop.2025.105128_bib3","series-title":"Deaths by Cause, Age, Sex, by Country and by Region, 2000\u20132019","year":"2020"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib4","first-page":"30","article-title":"American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity","volume":"62","author":"Kushi","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/OP.23.00494","article-title":"Cardiotoxicity of agents used in patients with breast cancer","volume":"20","author":"Zagami","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11864-019-0646-1","article-title":"Cardiotoxicity of contemporary breast cancer treatments","volume":"20","author":"Lee Chuy","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.esmoop.2025.105128_bib7","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1093\/eurheartj\/ehae637","article-title":"Breast cancer and cardiovascular health","volume":"45","author":"L\u00f3pez-Fern\u00e1ndez","year":"2024","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105128_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105128_bib9","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-Oncology Services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM197902083000603","article-title":"Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography","volume":"300","author":"Alexander","year":"1979","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105128_bib11","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105128_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"41","key":"10.1016\/j.esmoop.2025.105128_bib13","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib15","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105128_bib16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.amjmed.2021.05.026","article-title":"Chemotherapy-induced arrhythmia \u2013 underrecognized and undertreated","volume":"134","author":"Essa","year":"2021","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11936-020-00871-5","article-title":"Arrhythmias associated with inflammatory cardiomyopathies","volume":"22","author":"Karki","year":"2020","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.33678\/cor.2023.023","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"65","author":"Peichl","year":"2023","journal-title":"Cor Vasa"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105128_bib20","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105128_bib21","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.esmoop.2025.105128_bib22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105128_bib23","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105128_bib26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jacc.2018.12.046","article-title":"Recommendations for institutions transitioning to high-sensitivity troponin testing: JACC scientific expert panel","volume":"73","author":"Januzzi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105128_bib29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"Zardavas","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105128_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00041433-200308000-00003","article-title":"Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment","volume":"14","author":"Brennan","year":"2003","journal-title":"Curr Opin Lipidol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105128_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaccao.2023.12.009","article-title":"Circulating microRNA as biomarkers of anthracycline-induced cardiotoxicity","volume":"6","author":"Boen","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105128_bib33","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0959-8049(22)01560-X","article-title":"Circulating microRNAs for early detection of therapy-related cardiac events in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO","volume":"175","author":"Pizzamiglio","year":"2022","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105128_bib34","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105128_bib37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005521","article-title":"Global longitudinal strain by echocardiography predicts long-term risk of cardiovascular morbidity and mortality in a low-risk general population: the Copenhagen city heart study","volume":"10","author":"Biering-S\u00f8rensen","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105128_bib39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105128_bib40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"issue":"41","key":"10.1016\/j.esmoop.2025.105128_bib41","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","article-title":"Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial","volume":"45","author":"Marwick","year":"2024","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105128_bib42","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2009.11.011","article-title":"ACCF\/ACR\/AHA\/NASCI\/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on expert consensus documents","volume":"55","author":"Hundley","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib43","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jcmg.2020.10.024","article-title":"Fast strain-encoded cardiac magnetic resonance for diagnostic classification and risk stratification of heart failure patients","volume":"14","author":"Korosoglou","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.121.012459","article-title":"Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up","volume":"14","author":"Giusca","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.esmoop.2025.105128_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e17693","article-title":"Validation of heart failure prediction tool in cardio-oncology breast cancer population","volume":"33","author":"Rushton","year":"2015","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.esmoop.2025.105128_bib46","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105128_bib47","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/eurheartj\/ehae496","article-title":"Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score","volume":"46","author":"Rivero-Santana","year":"2025","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib50","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jacc.2017.05.035","article-title":"Impact of oxidative stress on the heart and vasculature: part 2 of a 3-part series","volume":"70","author":"M\u00fcnzel","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105128_bib52","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib54","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib55","article-title":"Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy","volume":"3","author":"van Dalen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105128_bib57","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2007.11.8778","article-title":"Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin\u2019s disease: a claim without compelling evidence","volume":"25","author":"Lipshultz","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105128_bib58","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer treatment\u2013induced arrhythmias: focus on chemotherapy and targeted therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cpt.2024.04.004","article-title":"Cardiotoxicity in platinum-based chemotherapy: mechanisms, manifestations, and management","volume":"3","author":"Rachma","year":"2024","journal-title":"Cancer Pathog Ther"},{"key":"10.1016\/j.esmoop.2025.105128_bib60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","article-title":"An integrative view of cisplatin-induced renal and cardiac toxicities: molecular mechanisms, current treatment challenges and potential protective measures","volume":"371","author":"Dugbartey","year":"2016","journal-title":"Toxicology"},{"key":"10.1016\/j.esmoop.2025.105128_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.esmoop.2025.105128_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103346","article-title":"Risk factors of fluoropyrimidine induced cardiotoxicity among cancer patients: a systematic review and meta-analysis","volume":"162","author":"Li","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy","volume":"106","author":"De Keulenaer","year":"2010","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105128_bib64","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105128_bib65","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01)","volume":"32","author":"De Azambuja","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105128_bib66","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105128_bib67","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib68","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105128_bib70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105128_bib71","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","article-title":"Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis","volume":"3","author":"Alhussein","year":"2021","journal-title":"CJC Open"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105128_bib72","doi-asserted-by":"crossref","first-page":"10607","DOI":"10.1073\/pnas.0701286104","article-title":"Activation of AMP-activated protein kinase by human EGF receptor 2\/EGF receptor tyrosine kinase inhibitor protects cardiac cells","volume":"104","author":"Spector","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"10.1016\/j.esmoop.2025.105128_bib73","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105128_bib74","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"De Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105128_bib75","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","article-title":"Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab Treatment Optimization Trial","volume":"122","author":"Eiger","year":"2020","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib76","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","article-title":"Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer the NEfERT-T randomized clinical trial","volume":"2","author":"Awada","year":"2016","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib77","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105128_bib78","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Eng J Med"},{"key":"10.1016\/j.esmoop.2025.105128_bib79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Pond\u00e9","year":"2020","journal-title":"Eur J Cancer"},{"issue":"suppl 9","key":"10.1016\/j.esmoop.2025.105128_bib80","first-page":"GS03","article-title":"Abstract GS03-12: phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis","volume":"84","author":"Loibl","year":"2024","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105128_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105128_bib82","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1002\/cncr.24508","article-title":"Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study","volume":"115","author":"Hernandez","year":"2009","journal-title":"Cancer"},{"issue":"9354","key":"10.1016\/j.esmoop.2025.105128_bib83","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105128_bib84","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1200\/JCO.2003.10.111","article-title":"Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105128_bib85","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/archinte.161.11.1405","article-title":"Use of statins and the subsequent development of deep vein thrombosis","volume":"161","author":"Ray","year":"2001","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib86","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.clinthera.2019.01.012","article-title":"Risk factors of QTc prolongation in women with hormone receptor\u2012positive\/human epidermal growth factor receptor 2\u2012negative metastatic breast cancer: a retrospective analysis of health care claims data","volume":"41","author":"Ward","year":"2019","journal-title":"Clin Ther"},{"issue":"10218","key":"10.1016\/j.esmoop.2025.105128_bib87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105128_bib88","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","article-title":"Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial","volume":"7","author":"Buzdar","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105128_bib89","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Khosrow-Khavar","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib90","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jnci\/djx141","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis","volume":"110","author":"Goldvaser","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105128_bib91","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study","volume":"141","author":"Khosrow-Khavar","year":"2020","journal-title":"Circulation"},{"issue":"30","key":"10.1016\/j.esmoop.2025.105128_bib92","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.esmoop.2025.105128_bib93","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105128_bib94","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105128_bib95","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2020.38.15_suppl.1023","article-title":"A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer","volume":"38","author":"Lim","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib96","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105128_bib97","first-page":"63","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"24","author":"Hurvitz","year":"2013","journal-title":"Breast Dis"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105128_bib98","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cam4.4579","article-title":"Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"issue":"27","key":"10.1016\/j.esmoop.2025.105128_bib99","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC clinical trials group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105128_bib101","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","article-title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"125","author":"Burris","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105128_bib102","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105128_bib103","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ctrv.2017.11.009","article-title":"Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs","volume":"63","author":"Coppola","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib104","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib105","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105128_bib106","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5 years of follow-up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib107","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105128_bib109","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105128_bib110","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105128_bib111","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105128_bib112","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105128_bib113","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib114","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib115","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib116","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11886-016-0731-z","article-title":"Curing cancer, saving the heart: a challenge that cardioncology should not miss","volume":"18","author":"Cardinale","year":"2016","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105128_bib117","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1161\/CIRCULATIONAHA.112.001183","article-title":"Ideal cardiovascular health is inversely associated with incident cancer the atherosclerosis risk in communities study","volume":"127","author":"Rasmussen-Torvik","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.esmoop.2025.105128_bib118","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pcad.2024.02.002","article-title":"Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: the ONCORE randomized controlled trial","volume":"85","author":"D\u00edaz-Balboa","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105128_bib119","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2025.105128_bib120","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105128_bib121","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105128_bib122","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105128_bib123","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy a randomized clinical trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105128_bib124","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105128_bib125","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105128_bib126","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105128_bib127","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib128","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1074248418821721","article-title":"Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial","volume":"24","author":"Nabati","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"27","key":"10.1016\/j.esmoop.2025.105128_bib130","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer","volume":"43","author":"Lewinter","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib131","first-page":"33","article-title":"Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial","volume":"7","author":"Mecinaj","year":"2021","journal-title":"Cardiooncology"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105128_bib132","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105128_bib133","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.018393","article-title":"Statin exposure and risk of heart failure after anthracycline-or trastuzumab-based chemotherapy for early breast cancer: a propensity score\u2012matched cohort study","volume":"10","author":"Abdel-Qadir","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105128_bib134","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1381612829666230217143324","article-title":"The emerging role of sodium-glucose cotransporter 2 inhibitors in heart failure","volume":"29","author":"Gitto","year":"2023","journal-title":"Curr Pharm Des"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105128_bib135","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib136","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib137","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"36","key":"10.1016\/j.esmoop.2025.105128_bib138","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"48","key":"10.1016\/j.esmoop.2025.105128_bib139","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105128_bib140","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10549-022-06586-4","article-title":"Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer","volume":"193","author":"Kwan","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105128_bib141","first-page":"43","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"66","author":"Runowicz","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105128_bib142","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:43Z","timestamp":1762598683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":142,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2059702925009974"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105128","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105128"}}